中国生命科学与医疗行业调研结果：2025年行业现状与展望（英）

China Life Sciences & Health Care TeamMarch 2025China LSHC Industry Survey 2025 State of Industry in China2China Life Science & Health Care Industry Survey – 2025 State of Industry in China© 2025. For information, contact Deloitte China.Content◼ Framework◼ Results – Questions & Deep-dive•China LSHC Business Outlook & Considerations•New regulatory and technology impact•New shifts in business investment strategy◼ Concluding insights◼ Appendix3China Life Science & Health Care Industry Survey – 2025 State of Industry in China© 2025. For information, contact Deloitte China.Note: SOE – State-owned Enterprise; POE – Private-owned Enterprise; JV – Joint Venture; WOFE – Wolly Foreign-owned Enterprises:HC – HealthcareSurvey period: January 2025 (closed February 7, 2025)Engaged 125 China-based Life Science & Health Care (‘LSHC’) industry operators and investorsFramework56%11%25%8%WOFEJVPOESOE23%42%34%Chairman/ CEOC-suite levelOther management team74%4%18%4%BiopharmaMedTechDistributorsHC services46%23%15%16%Over 5 billion1 - 5 billion100 million - 1billionLess than 100millionCompany type distributionIndustry sector distributionSeniority level distributionChina revenue (RMB) size distribution4China Life Science & Health Care Industry Survey – 2025 State of Industry in China© 2025. For information, contact Deloitte China.China LSHC outlook & considerations5China Life Science & Health Care Industry Survey – 2025 State of Industry in China© 2025. For information, contact Deloitte China.Note: Large cos – company with 2024 revenue exceed RMB 1 billion; SOE – State-owned Enterprise; POE – Private-owned Enterprise; WOFE – Wolly Foreign-owned EnterprisesWhile China’s business performance in 2024 exceeded that of 2023, it remained below expectations. Local players continued to face heightened commercialization pressures throughout the year > China LSHC industry outlook & considerations – business performance26%34%40%31%29%40%Better thanplannedIn line with plansWorse thanplanned54%19%26%Better than 2023In line with 2023Worse than 2023How did your company perform (top line) in 2024?2025 Survey2024 SurveyCompared to previous year (2023)Compared to expectations/ plans26%38%36%41%28%31%22%29%49%28%31%41%33%26%41%50%16%34%28%38%34%31%26%43%AllLarge cosSOE&POEWOFEBiopharma56%20%24%49%17%34%54%24%22%58%20%22%AllLarge cosSOE&POEWOFEBiopharmaKey observations•Majority (54%) of respondents saw their 2024 China business exceeded of 2023✓ One-fifth had no or little growth, and foreign companies have nearly one-fourth with limited growth✓ SOE/POE seem to have suffered more•But expectations were higher✓ While only 26% exceeded their plans – a combined 60% reached plan or better (same last year) – yet 40% came out worse✓ Foreign companies were prudent in planning – also 33% exceeded plan ✓ SOE/POE and MedTech to the contrary had ca. 50% showing worse results than plannedBusiness performance45%18%36%MedTech14%32%55%36%32%32%MedTech6China Life Science & Health Care Industry Survey – 202